Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

被引:66
|
作者
Song, Gina [1 ]
Wu, Huali [1 ]
Yoshino, Keisuke
Zamboni, William C. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Mol Therapeut Program, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, UNC Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Carolina Ctr Canc Nanotechol Excellence, Chapel Hill, NC 27599 USA
[5] N Carolina Biomedial Innovat Network, Chapel Hill, NC USA
关键词
pharmacokinetics; pharmacodynamics; liposomes; STERICALLY STABILIZED LIPOSOMES; TEMPERATURE-SENSITIVE LIPOSOMES; LARGE UNILAMELLAR LIPOSOMES; HUMAN TUMOR XENOGRAFT; PHASE-II TRIAL; IN-VIVO; POPULATION PHARMACOKINETICS; PROLONGED CIRCULATION; POLYETHYLENE-GLYCOL; CKD-602; S-CKD602;
D O I
10.3109/08982104.2012.655285
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Various attempts to increase the therapeutic index of the drug while minimizing side effects have been made in drug delivery systems. Among several promising strategies, liposomes represent an advanced technology to target active molecules to the site of action. Rapid clearance of circulating liposomal drugs administered intravenously has been a critical issue because circulation time in the blood affects drug exposure at the target site. The clinical use of liposomal drugs is complicated by large intra-and interindividual variability in their pharmacokinetics (PK) and pharmacodynamics (PD). Thus, it is important to understand the factors affecting the PK/PD of the liposomal formulation of drugs and to elucidate the mechanisms underlying the variability in the PK/PD of liposomal drugs. In this review article, we describe the characteristics of liposome formulations and discuss the effects of various factors, including liposome-associated factors, host-associated factors, and treatment on the PK/PD of liposomal agents.
引用
收藏
页码:177 / 192
页数:16
相关论文
共 50 条
  • [12] Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs
    Yu, Xue-Qing
    Xue, Charlie Changli
    Wang, Guangji
    Zhou, Shu-Feng
    CURRENT DRUG METABOLISM, 2007, 8 (08) : 787 - 802
  • [13] Liposomal formulations of cyclosporin A: A biophysical approach to pharmacokinetics and pharmacodynamics
    Fahr, A
    Seelig, J
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2001, 18 (02): : 141 - 172
  • [14] Liposomal amphotericin B: Clinical pharmacology, pharmacokinetics and pharmacodynamics
    Azanza Perea, Jose Ramon
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2021, 38 (02): : 52 - 55
  • [15] Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of nanoparticle and nanosomal anticancer agents
    Zamboni, W.
    Wu, H.
    La-Beck, N.
    Gehrig, P.
    Song, G.
    Walsh, M. H. S.
    Gabizon, A.
    Ramanathan, R.
    Caron, W.
    EJC SUPPLEMENTS, 2010, 8 (07): : 17 - 17
  • [16] The role of transporters in pharmacokinetics and pharmacodynamics of drugs
    Unadkat, J. Jash D.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 : S106 - S106
  • [17] Drugs in space: Pharmacokinetics and pharmacodynamics in astronauts
    Kast, Johannes
    Yu, Yichao
    Seubert, Christoph N.
    Wotring, Virginia E.
    Derendorf, Hartmut
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : S2 - S8
  • [18] PHARMACOKINETICS AND RELATED PHARMACODYNAMICS OF ANTICHOLINERGIC DRUGS
    ALIMELKKILA, T
    KANTO, J
    IISALO, E
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1993, 37 (07) : 633 - 642
  • [19] Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs
    Budha, Nageshwar R.
    Lee, Richard E.
    Meibohm, Bernd
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (08) : 809 - 825
  • [20] Genetics and the pharmacokinetics and pharmacodynamics of psychiatric drugs
    Mancama, D
    Kerwin, RW
    Arranz, MJ
    PHARMACOPSYCHIATRY, 2005, 38 (01) : 57 - 57